Prometheus Biosciences Launches Monitr™ COVID-19 Assistance Program (M.C.A.P.)

The PROMETHEUS® Monitr Crohn’s Disease Test is being offered through M.C.A.P., at no cost to qualifying patients*

Prometheus’ Monitr CD test, a noninvasive, serum-based test that can aid in the assessment of endoscopic disease activity in conjunction with other clinical findings

SAN DIEGO, March 23, 2020 /PRNewswire/ — Prometheus Biosciences, Inc. (“Prometheus”), a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced today that it has launched the Monitr™ COVID-19 Assistance Program (M.C.A.P.) to provide adult Crohn’s disease (CD) patients with access to this valuable test.

“During these unprecedented times, our focus at Prometheus continues to remain on the patients we serve. With the launch of M.C.A.P., we are providing qualifying adult CD patients impacted by COVID-19 with an effective disease-monitoring test at no cost,” said Mark McKenna, President and CEO of Prometheus. “We believe that the adoption of this program by GI physicians could minimize the burden on Crohn’s disease patients as the novel coronavirus continues to impact the global healthcare system. We are working on continued access to our mobile phlebotomy services to facilitate sample collection and mitigate the need for your patients to engage in any unnecessary travel.”

As a direct result of the COVID-19 pandemic, many healthcare providers have canceled or may soon cancel elective outpatient colonoscopies that are used to assess the mucosal status of CD patients. As a result, physicians may need to make therapy decisions for patients with CD without the objective data provided by colonoscopy regarding disease activity. Prometheus’ commercially-available Monitr test, a first-of-its kind, noninvasive serum test aids in distinguishing CD patients in endoscopic remission from those with active disease, enabling more informed treatment management decisions. The Monitr test has been validated, and results presented in Gastroenterology.

Maria T. Abreu, M.D., Director of the Crohn’s and Colitis Center, University of Miami Health System, commented, “As physicians who care for IBD patients, we want to make the best decisions about medications for our patients, especially in the face of COVID-19. Most of us have taken the measure to delay colonoscopies in our patients and we don’t know when it will be safe to have patients return for colonoscopies. I am happy that our Crohn’s patients can benefit from Monitr as a way of determining active disease or healed mucosa. Having patients avoid hospitals and laboratories all together is great during this special situation.”

About the Monitr COVID-19 Assistance Program (M.C.A.P.)

Prometheus Biosciences launched its Monitr COVID-19 Assistance Program to support patients with adult Crohn’s disease. Through this assistance program, Prometheus is providing the Monitr test at no charge for those patients who have lost employment and/or commercial insurance coverage as a result of the COVID-19 outbreak.* This program will be available to all qualifying patients from March 23, 2020 through June 1, 2020 where Prometheus Biosciences acts as the billing entity. For all other patients, Prometheus’ existing financial assistance programs are still available. In addition, Prometheus is also working on continued, uninterrupted access to mobile phlebotomy services to facilitate sample collection and mitigate the need for patients to engage in any unnecessary travel. If you have any questions on how to order the Prometheus Monitr CD test, please contact Prometheus’ client services team at 888-423-5227.

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, is headquartered in San Diego, California. For more information about Prometheus, please visit us at www.prometheusbiosciences.com.

Contacts:

Investor Relations and Media Contact

Juniper Point
Amy Conrad, (858) 914-1962
IR@prometheusbiosciences.com

Connor Glenn, (858) 200-7888
info@prometheusbiosciences.com

SOURCE Prometheus Biosciences, Inc.

Related Links
http://www.prometheusbiosciences.com

Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer

Prometheus Biosciences Appoints Dr. Thierry Dervieux as Chief Development Officer


SAN DIEGO, Dec. 10, 2019 /PRNewswire/ —  Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology (GI) and autoimmune diseases, announced today the appointment of Thierry Dervieux, PharmD, PhD, DABCC as chief development officer, diagnostics, and medical laboratory director.   

“Thierry’s deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions,” said Mark McKenna, chief executive officer of Prometheus Biosciences. “We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.”

Dr. Dervieux joins Prometheus Biosciences from Exagen Diagnostics, a diagnostic company focused on chronic autoimmune diseases, where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr. Dervieux was vice president of research and development at Cypress Bioscience, Inc. and senior director of research and development with Proprius Pharmaceuticals, Inc. (acquired by Cypress Bioscience, Inc.). Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories. Dr. Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, genetic testing, and diagnostic immunology. Dr. Dervieux holds PharmD and PhD degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from Pierre and Marie Curie University in Paris, France, and trained at St. Jude Children’s Research Hospital in Memphis, Tennessee.

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, is headquartered in San Diego, California. For more information about Prometheus, please visit us at www.prometheusbiosciences.com.

Contacts:

Investor Relations and Media Contact
Juniper Point
Amy Conrad, (858) 914-1962
IR@prometheusbiosciences.com

Connor Glenn, (858) 200-7888
info@prometheusbiosciences.com

Prometheus Biosciences, Inc., Enters Into Multi-Target Strategic Collaboration with Takeda to Develop Targeted Therapies for Inflammatory Bowel Disease

Agreement Leverages Prometheus Biosciences’ Proprietary Bioinformatics Analysis Platform, Companion Diagnostics to Speed Development and Discovery

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ —  Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced that it has entered into a global, multi-target strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) to discover, develop, and commercialize novel therapies for inflammatory bowel disease (IBD). The collaboration combines the proprietary bioinformatics discovery platform and companion diagnostic tools developed by Prometheus Biosciences with Takeda’s expertise in gastroenterology and drug development, in order to discover and advance up to three targeted IBD therapeutics and companion diagnostics.   

Prometheus Biosciences will be responsible for the identification and validation of three unique drug targets for IBD, along with the development and commercialization of companion diagnostics to complement the targeted drugs. Takeda will be responsible for all drug discovery, clinical development, and commercialization activities for the resulting targeted therapeutics. 

 “We are impressed with Takeda’s commitment to developing a portfolio of therapies to address all IBD patients, especially those with unmet needs,” said Mark McKenna, chief executive officer, Prometheus Biosciences.  “We believe that a targeted, precision medicine approach is needed to deliver new, effective therapeutic options in inflammatory bowel disease. Through our partnership, we are excited to combine the Prometheus bioinformatics platform and advanced machine learning techniques with Takeda’s expertise in drug development to deliver a new generation of IBD therapies.”

Under the terms of the agreement, Prometheus Biosciences will receive an undisclosed initial upfront payment from Takeda and is eligible to receive up to $420M in development, regulatory, and commercial milestone payments, in total, across all three programs. In addition, Prometheus Biosciences is eligible to receive royalty payments on global commercial sales from each program. 

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, is headquartered in San Diego, California. For more information about Prometheus, please visit us atwww.prometheusbiosciences.com.

Contacts:

Investor Relations and Media Contact
Juniper Point
Amy Conrad
(858) 914-1962
IR@prometheusbiosciences.com
 

Prometheus Biosciences
Connor Glenn
(858) 200-7888 
info@prometheusbiosciences.com

SOURCE Prometheus Biosciences, Inc.

Related Links
https://www.prnewswire.com/news-releases/prometheus-biosciences-inc-enters-into-multi-target-strategic-collaboration-with-takeda-to-develop-targeted-therapies-for-inflammatory-bowel-disease-300931019.html?tc=eml_cleartime

Prometheus Biosciences Strengthens Executive Management Team with New Appointments

SAN DIEGO, Oct. 28, 2019 /PRNewswire/ — Prometheus Biosciences, Inc., a biopharmaceutical company, announced today the appointments of Chris Slavinsky as general counsel and head of business development, and Mike Walther as chief commercial officer, to its executive management team. Prometheus Biosciences is committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

“We are excited to welcome Chris and Mike to the Prometheus Biosciences team, as they bring decades of legal, commercial, and transactional expertise in the gastroenterology field,” said Mark McKenna, chief executive officer of Prometheus Biosciences. “Their contributions will be critical as we advance our mission to revolutionize the development of diagnostics and therapeutics for gastroenterology.”

Mr. Slavinsky joins Prometheus Biosciences from Takeda, where he served as vice president of the Takeda Center for External Innovation, and head of Gastroenterology Business Development, Externalization and Special Projects. Prior to joining Takeda, Chris served in several key roles at Pfizer over a 17-year period, including chief counsel of several Pfizer business segments including business transactions, R&D, medical technologies, and anti-infectives. Mr. Slavinsky serves as a member of the board of directors of Phathom Pharmaceuticals and ARTham Therapeutics. Mr. Slavinsky received a J.D. from the Washington University in St. Louis School of Law, an M.S. in biochemistry and molecular biology from Thomas Jefferson University, and a B.S. in biochemistry from the State University of New York at Stony Brook.

Mike Walther joins Prometheus Biosciences from Aries Pharmaceuticals, where he last served as general manager, establishing corporate, pipeline, and portfolio strategies including the commercial launch of the company’s first 2 products. Mr. Walther’s industry experience spans numerous therapeutic markets, most notably a 25-year focus in pharmaceutical, medical device, and diagnostics product development and commercialization in gastroenterology. Prior to joining Aries, Mr. Walther was vice president, Commercial Development at Prometheus Laboratories Inc., where he was responsible for commercializing specialty therapeutics and proprietary diagnostic testing services designed to advance patient-personalized care, and previously held roles spanning sales, specialty marketing, and commercial operations at Takeda Pharmaceuticals North America and TAP Pharmaceuticals (a Takeda Pharmaceuticals and Abbott Laboratories partnership). Mr. Walther received his B.A. in biology from Ithaca College.

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD, is headquartered in San Diego, California. For more information about Prometheus, please visit us at www.prometheusbiosciences.com.

Contacts:

Investor Relations and Media Contact
Juniper Point
Amy Conrad, (858) 914-1962
IR@prometheusbiosciences.com

Connor Glenn, (858) 200-7888
info@prometheusbiosciences.com

Precision IBD Announces Next Phase Of Growth: Appoints Mark C. McKenna As President And Chief Executive Officer, Completes Name Change To Prometheus Biosciences, Inc.

Company Plans to Complete Series C Financing in Fourth Quarter of 2019, Followed by Initial Public Offering for 2020

SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — Precision IBD, Inc., a biopharmaceutical company focused on the discovery and development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease (IBD), today announced the appointment of Mark C. McKenna as the company’s chief executive officer, and the completion of the company’s name change to Prometheus Biosciences, Inc. The announcements reflect the company’s strategic focus of applying precision medicine to develop targeted therapies for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences will serve as the name for the combined companies Precision IBD and Prometheus Laboratories, Inc., created through the June 2019 acquisition of Prometheus Laboratories by Precision IBD.

Mr. McKenna succeeds Precision IBD’s current CEO Scott Glenn, who co-founded Precision IBD and over a dozen successful biotech companies. Glenn will continue to serve as an active member of the board and advisor to the new CEO.  

“We are grateful to Scott for his vision and drive to position Prometheus Biosciences as an emerging leader in the fast-changing healthcare industry. We look forward to his continued contributions to the company as a valued member of the board,” said Dr. Tadataka (Tachi) Yamada, chairman of the board. “The board and I welcome Mark as the new CEO and are confident that he is the right person to lead our company into its next phase of growth.”

“I am incredibly excited to assume this new role, and for the future of Prometheus Biosciences. We have a world-class company that allows for precise therapeutic drug discovery, top-notch clinical and healthcare strategists on our board of directors’ team, and a robust GI pipeline of diagnostic and therapeutic drugs,” said Mark McKenna, chief executive officer, Prometheus Biosciences. “The new name leverages our heritage as the preeminent GI diagnostic company, as well as signals the broader vision to rapidly expand our innovative therapeutic business through ongoing development programs and licensing and acquisition of marketed therapeutic assets.”

Mr. McKenna will join Prometheus Biosciences from Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. During his tenure as president at Salix, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance.

Prior to joining Salix, Mr. McKenna spent more than a decade in leadership roles with Bausch + Lomb, where the team successfully reversed seven years of declining sales, revitalized the product pipeline, and increased market share. 

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Prometheus Biosciences, Inc., is headquartered in San Diego, California. For more information about Prometheus, please visit us at www.prometheusbiosciences.com.

Media Contact:
Katja Bogle, (858) 587-4149
pr@prometheusbiosciences.com

Connor Glenn, (858) 200-7888
info@prometheusbiosciences.com

SOURCE Prometheus Biosciences, Inc.

Related Links
www.prometheusbiosciences.com